Thursday, August 4, 2011

Sun Pharma - Prandin generics in US expected around mid 2012

The court conducted the litigation between Sun's subsdiary Caraco and Novo Nordisk is expected to rule on Prandin generics around 2012. Prandin sales in the US is ~ DKK 1000m ( ~ $150m). This should translate into a $30m EBIT opportunity for Sun Pharma in 2012.